# PATAPSCO (NCT05943106)

> BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05943106
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Non-Muscle- Invasive Bladder Cancer
- Interventions: Durvalumab; BCG
- Enrollment: 100
- Primary outcome: Incidence of Grade 3 or 4 Possibly related adverse events (PRAEs)

## Commentary we found

- YouTube: 6
- Podcasts: 3
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=patapsco-nct05943106

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05943106", "email": "<work email>"}; the inbox owner confirms by the emailed link.